427 related articles for article (PubMed ID: 34558862)
21. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
Golabi P; Paik JM; Kumar A; Al Shabeeb R; Eberly KE; Cusi K; GunduRao N; Younossi ZM
Metabolism; 2023 Sep; 146():155642. PubMed ID: 37380016
[TBL] [Abstract][Full Text] [Related]
22. Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease.
Kim HY; Baik SJ; Lee HA; Lee BK; Lee HS; Kim TH; Yoo K
Sci Rep; 2020 Oct; 10(1):17491. PubMed ID: 33060775
[TBL] [Abstract][Full Text] [Related]
23. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
[TBL] [Abstract][Full Text] [Related]
24. Liver-related Mortality is Increased in Lean Subjects with Non- alcoholic Fatty Liver Disease Compared to Overweight and Obese Subjects.
Feldman A; Wernly B; Strebinger G; Eder SK; Zandanell S; Niederseer D; Strasser M; Haufe H; Sotlar K; Paulweber B; Datz C; Aigner E
J Gastrointestin Liver Dis; 2021 Sep; 30(3):366-373. PubMed ID: 34375373
[TBL] [Abstract][Full Text] [Related]
25. Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease.
Ishido S; Tamaki N; Takahashi Y; Uchihara N; Suzuki K; Tanaka Y; Miyamoto H; Yamada M; Matsumoto H; Nobusawa T; Keitoku T; Takaura K; Tanaka S; Maeyashiki C; Yasui Y; Tsuchiya K; Nakanishi H; Kurosaki M; Izumi N
BMC Gastroenterol; 2023 Jun; 23(1):211. PubMed ID: 37330485
[TBL] [Abstract][Full Text] [Related]
26. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
27. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases.
Weinberg EM; Trinh HN; Firpi RJ; Bhamidimarri KR; Klein S; Durlam J; Watkins S; Reddy KR; Weiss M; Zink RC; Lok AS
Clin Gastroenterol Hepatol; 2021 May; 19(5):996-1008.e6. PubMed ID: 32629123
[TBL] [Abstract][Full Text] [Related]
28. Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Lu FB; Zheng KI; Rios RS; Targher G; Byrne CD; Zheng MH
J Gastroenterol Hepatol; 2020 Dec; 35(12):2041-2050. PubMed ID: 32573017
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease.
Kim Y; Han E; Lee JS; Lee HW; Kim BK; Kim MK; Kim HS; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Lee YH; Kim SU
Gut Liver; 2022 Mar; 16(2):290-299. PubMed ID: 34238770
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China.
Lan Y; Lu Y; Li J; Hu S; Chen S; Wang Y; Yuan X; Liu H; Wang X; Wu S; Wang L
Hepatol Commun; 2022 Dec; 6(12):3393-3405. PubMed ID: 36281973
[TBL] [Abstract][Full Text] [Related]
31. Gamma-glutamyl transferase and cardiovascular risk in nonalcoholic fatty liver disease: The Gut and Obesity Asia initiative.
Pitisuttithum P; Chan WK; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Dan YY; Imajo K; Nakajima A; Ho KY; Goh KL; Wong VW; Treeprasertsuk S
World J Gastroenterol; 2020 May; 26(19):2416-2426. PubMed ID: 32476802
[TBL] [Abstract][Full Text] [Related]
32. Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease.
Chun HS; Lee M; Lee HA; Lee S; Kim S; Jung YJ; Lee C; Kim H; Lee HA; Kim HY; Yoo K; Kim TH; Ahn SH; Kim SU
Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2298-2307.e18. PubMed ID: 36462755
[TBL] [Abstract][Full Text] [Related]
33. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
34. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
Chakrabarty M; Jha AN; Sharma DJ
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
[TBL] [Abstract][Full Text] [Related]
35. Association between fasting plasma glucose and nonalcoholic fatty liver disease in a nonobese Chinese population with normal blood lipid levels: a prospective cohort study.
Zou Y; Yu M; Sheng G
Lipids Health Dis; 2020 Jun; 19(1):145. PubMed ID: 32563249
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
Lee H; Lee YH; Kim SU; Kim HC
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
[TBL] [Abstract][Full Text] [Related]
37. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes.
Li M; Zhao Z; Qin G; Chen L; Lu J; Huo Y; Chen L; Zeng T; Xu M; Chen Y; Wang T; Wang S; Xu Y; Shi L; Tang X; Su Q; Yu X; Yan L; Wan Q; Chen G; Gao Z; Wang G; Shen F; Luo Z; Zhang Y; Liu C; Wang Y; Hu R; Ye Z; Wu S; Deng H; Yang T; Li Q; Qin Y; Mu Y; Zhao J; Ning G; Bi Y; Xu Y; Wang W
Metabolism; 2021 Nov; 124():154874. PubMed ID: 34517014
[TBL] [Abstract][Full Text] [Related]
38. Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population.
Li MR; Li JZ; Li JY; Wang CC; Yuan RK; Ye LH; Liu YY; Liang XJ; Zhang HC; Liu ZQ; Zeng DY; Zhang XD; Wang DH; Li JQ; Li TY; Yang L; Cao Y; Pan Y; Lin XG; Pan CQ; Dai EH; Dong ZY
Obes Facts; 2023; 16(5):427-434. PubMed ID: 37231905
[TBL] [Abstract][Full Text] [Related]
39.
Sakamoto Y; Oniki K; Kumagae N; Morita K; Otake K; Ogata Y; Saruwatari J
Dis Markers; 2019; 2019():4065327. PubMed ID: 31929840
[TBL] [Abstract][Full Text] [Related]
40. Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
Simon TG; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Gut; 2022 Sep; 71(9):1867-1875. PubMed ID: 34489307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
